600812 华北制药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)1.3520.092-12.1070.3071.650
总资产报酬率 ROA (%)0.3370.023-2.9870.0770.454
投入资产回报率 ROIC (%)0.4110.028-3.5930.0910.484

边际利润分析
销售毛利率 (%)29.89831.98133.38035.45635.770
营业利润率 (%)2.8211.546-5.4061.3101.602
息税前利润/营业总收入 (%)7.0826.238-0.1296.8506.647
净利润/营业总收入 (%)1.8640.488-6.4650.3410.909

收益指标分析
经营活动净收益/利润总额(%)77.47148.541-33.27119.75138.671
价值变动净收益/利润总额(%)14.85829.552-7.79028.99614.161
营业外收支净额/利润总额(%)1.6141.314-0.453-0.8351.356

偿债能力分析
流动比率 (X)0.7690.7810.7240.8931.030
速动比率 (X)0.5400.5270.5210.7250.822
资产负债率 (%)69.86670.07970.65071.85270.518
带息债务/全部投入资本 (%)68.72867.43867.07069.084--
股东权益/带息债务 (%)43.87045.40745.22242.17445.215
股东权益/负债合计 (%)35.08636.19235.35233.97336.290
利息保障倍数 (X)1.6801.335-0.0241.2341.323

营运能力分析
应收账款周转天数 (天)72.17674.02671.82664.0120.000
存货周转天数 (天)127.949134.173126.481130.1090.000